126 related articles for article (PubMed ID: 23801280)
1. Enhanced SOX10 and KIT expression in cutaneous melanoma.
Rönnstrand L; Phung B
Med Oncol; 2013; 30(3):648. PubMed ID: 23801280
[No Abstract] [Full Text] [Related]
2. SOX10 expression in malignant melanoma, carcinoma, and normal tissues.
Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):506-10. PubMed ID: 23197006
[TBL] [Abstract][Full Text] [Related]
3. Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.
Blokzijl A; Chen LE; Gustafsdottir SM; Vuu J; Ullenhag G; Kämpe O; Landegren U; Kamali-Moghaddam M; Hedstrand H
PLoS One; 2016; 11(4):e0154214. PubMed ID: 27110718
[TBL] [Abstract][Full Text] [Related]
4. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
5. SOX10 expression in superficial spreading and nodular malignant melanomas.
Agnarsdóttir M; Sooman L; Bolander A; Strömberg S; Rexhepaj E; Bergqvist M; Ponten F; Gallagher W; Lennartsson J; Ekman S; Uhlen M; Hedstrand H
Melanoma Res; 2010 Dec; 20(6):468-78. PubMed ID: 20890226
[TBL] [Abstract][Full Text] [Related]
6. RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway.
Alonso-Curbelo D; Riveiro-Falkenbach E; Pérez-Guijarro E; Cifdaloz M; Karras P; Osterloh L; Megías D; Cañón E; Calvo TG; Olmeda D; Gómez-López G; Graña O; Sánchez-Arévalo Lobo VJ; Pisano DG; Wang HW; Ortiz-Romero P; Tormo D; Hoek K; Rodríguez-Peralto JL; Joyce JA; Soengas MS
Cancer Cell; 2014 Jul; 26(1):61-76. PubMed ID: 24981740
[TBL] [Abstract][Full Text] [Related]
7. Rapid SOX10 Immunostain on Fresh Frozen Tissue.
Donaldson MR; Deeths MJ; Weber LA
Dermatol Surg; 2016 Feb; 42(2):269-71. PubMed ID: 26808180
[No Abstract] [Full Text] [Related]
8. A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies.
Schartl M; Wilde B; Laisney JA; Taniguchi Y; Takeda S; Meierjohann S
J Invest Dermatol; 2010 Jan; 130(1):249-58. PubMed ID: 19609310
[TBL] [Abstract][Full Text] [Related]
9. Can SOX-10 or KBA.62 Replace S100 Protein in Immunohistochemical Evaluation of Sentinel Lymph Nodes for Metastatic Melanoma?
Vrotsos E; Alexis J
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):26-9. PubMed ID: 25611246
[TBL] [Abstract][Full Text] [Related]
10. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.
Shakhova O; Cheng P; Mishra PJ; Zingg D; Schaefer SM; Debbache J; Häusel J; Matter C; Guo T; Davis S; Meltzer P; Mihic-Probst D; Moch H; Wegner M; Merlino G; Levesque MP; Dummer R; Santoro R; Cinelli P; Sommer L
PLoS Genet; 2015 Jan; 11(1):e1004877. PubMed ID: 25629959
[TBL] [Abstract][Full Text] [Related]
11. Refining diagnosis is the prerequisite for the correct treatment: The cytodiagnostic utility of SOX10 in the diagnosis of metastatic melanoma.
Kilitçi A; Elmas ÖF; Demirbaş A; Gamsızkan M; Atasoy M; Türsen Ü; Lotti T
Dermatol Ther; 2021 Jan; 34(1):e14657. PubMed ID: 33301211
[No Abstract] [Full Text] [Related]
12. FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.
Wang J; Li L; Liu S; Zhao Y; Wang L; Du G
Oncotarget; 2016 Dec; 7(51):84375-84387. PubMed ID: 27533251
[TBL] [Abstract][Full Text] [Related]
13. High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness.
Long E; Ilie M; Bence C; Butori C; Selva E; Lalvée S; Bonnetaud C; Poissonnet G; Lacour JP; Bahadoran P; Brest P; Gilson E; Ballotti R; Hofman V; Hofman P
Cancer Med; 2016 Jun; 5(6):1022-30. PubMed ID: 26945789
[TBL] [Abstract][Full Text] [Related]
14. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
[TBL] [Abstract][Full Text] [Related]
16. [Epigenetic regulation of gene expression in malignant melanoma].
Laurette P; Koludrovic D; Coassolo S; Davidson I
Biol Aujourdhui; 2016; 210(4):283-295. PubMed ID: 28327285
[TBL] [Abstract][Full Text] [Related]
17. Neural crest stem cells in melanoma development.
Shakhova O
Curr Opin Oncol; 2014 Mar; 26(2):215-21. PubMed ID: 24441506
[TBL] [Abstract][Full Text] [Related]
18. The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion.
Graf SA; Heppt MV; Wessely A; Krebs S; Kammerbauer C; Hornig E; Strieder A; Blum H; Bosserhoff AK; Berking C
Pigment Cell Melanoma Res; 2019 May; 32(3):424-434. PubMed ID: 30506895
[TBL] [Abstract][Full Text] [Related]
19. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
20. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.
Shakhova O; Zingg D; Schaefer SM; Hari L; Civenni G; Blunschi J; Claudinot S; Okoniewski M; Beermann F; Mihic-Probst D; Moch H; Wegner M; Dummer R; Barrandon Y; Cinelli P; Sommer L
Nat Cell Biol; 2012 Aug; 14(8):882-90. PubMed ID: 22772081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
